Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

Novartis presents strong results in rare blood disorder trials

June 10, 2016 Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder

Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …
News
janssen_latest_logo_on_sign

Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma

June 10, 2016 Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma

Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma.  The company said …
News

Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation

June 10, 2016 Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) in a provisional guidance said Bayer’s (ETR: BAYN) Eylea (aflibercept) is …
News

FDA targets online illegal prescription drugs sellers

June 10, 2016 Medical Communications, Sales and Marketing FDA, Ireland, illegal drug sales

The US Food and Drug Administration (FDA), in partnership with an INTERPOL-led global collaborative effort, has announced that it has …
News
cipla

India-based Cipla gets new chief financial officer

June 8, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cipla, Dr Reddy's, cfo, dr reddys

Cipla (NSE: CIPLA) has poached a top executive from Dr. Reddy’s by naming Kedar Upadhye as its new global chief …
Appointment
ascologo

Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study

June 7, 2016 Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social

Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …
Feature
clinical_trial_4

The Pharmafocus ASCO round-up

June 7, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus

As the curtain falls on another annual ASCO (American Society of Clinical Oncology) congress, catch up on all the biggest …
Feature
novo_flag

Novo Nordisk presents positive long-term results for Saxenda

June 3, 2016 Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss

Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …
News
shire_image_4

Shire completes Baxalta takeover

June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales

UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT).  The …
News
lab

Eisai partners with Novartis in renal cell carcinoma collaboration

June 3, 2016 Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate

Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
News

Bayer, Orion to start Phase III trials for prostate cancer drug

June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research

German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
News

New FDA expanded access guidelines spell trouble for Sarepta

June 2, 2016 Medical Communications, Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, Eteplirsen, FDA, compassionate grounds, sarepta

New guidelines intended to streamline the process of expanded access to medicines by the US Food and Drug Administration (FDA) …
News
janssen_latest_logo_on_sign_closer

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016 Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …
News

Nice rejects Janssen’s Imbruvica in draft guidance

June 1, 2016 Medical Communications, Research and Development

The UK regulators have not recommended Janssen’s leukaemia drug Imbruvica (ibrutinib) to treat in draft guidance. The National Institute for …
News
biogen_idec_hillerod_2008

Biogen says European regulatory committee adopts positive view for Tysabri

June 1, 2016 Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis

Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025